Karyopharm Therapeutics (NASDAQ: KPTI) reported Q2 EPS of ($0.62), $0.01 better than the analyst estimate of ($0.63). Revenue for the quarter came in at $39.7 million versus the consensus estimate of $35.96 million.

GUIDANCE:

Karyopharm Therapeutics sees FY2022 revenue of $155-165 million, versus the consensus of $160 million.

For earnings history and earnings-related data on Karyopharm Therapeutics (KPTI) click here.